Physician profile
Valentin Hernandez
NPI 1871520320
$16,209.98
in general payments reported to CMS, 2019-2025
30 companies · $614 in 2025
The $614 reported for 2025 was more than what 77% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,665 · 2020: $2,767 · 2021: $2,764 · 2022: $2,609 · 2023: $2,384 · 2024: $1,407 · 2025: $614.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,405.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,404.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $3,084.75 | 2019-2023 | Xarelto |
| Astrazeneca Pharmaceuticals Lp | $3,034.04 | 2019-2025 | Airsupra, Farxiga, Wainua |
| Glaxosmithkline, LLC. | $2,699.84 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbvie INC. | $928.56 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $914.59 | 2019-2024 | Jardiance, Synjardy, Tradjenta |
| Lilly USA, LLC | $909.37 | 2019-2025 | Mounjaro, Trulicity, Zepbound |
| Pfizer INC. | $549.63 | 2019-2025 | |
| Amarin Pharma, INC. | $506.08 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $451.04 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $395.73 | 2021-2023 | |
| Allergan, INC. | $368.69 | 2019-2020 | |
| Dexcom, INC. | $339.85 | 2022-2024 | Dexcom G6 Transmitter |
| Novartis Pharmaceuticals Corporation | $313.45 | 2019-2023 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $247.79 | 2022 | |
| Amgen INC. | $233.75 | 2023-2025 | Repatha, Tepezza, Repatha |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $222.80 | 2020-2022 | |
| Biohaven Pharmaceuticals, INC. | $166.53 | 2021 | |
| Horizon Therapeutics Plc | $140.47 | 2020-2023 | Tepezza |
| E.R. Squibb & Sons, L.L.C. | $129.08 | 2019-2023 | Eliquis, Camzyos |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $97.47 | 2019 | |
| Novo Nordisk INC | $89.99 | 2021-2023 | |
| Sumitomo Pharma America, INC. | $71.00 | 2025 | Gemtesa |
| Sunovion Pharmaceuticals INC. | $70.74 | 2020 | |
| Vistapharm, INC. | $61.47 | 2021 | |
| Sanofi-Aventis U.S. LLC | $44.36 | 2019-2022 | |
| Mannkind Corporation | $41.66 | 2020 | |
| Ucb, INC. | $31.03 | 2019 | |
| Abbott Laboratories | $27.83 | 2023 | Freestyle Libre 3 |
| Nestle Healthcare Nutrition INC. | $19.83 | 2021 | |
| Sanofi Pasteur INC. | $18.56 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Valentin Hernandez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.